Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients - PubMed (original) (raw)

. 2004 Mar 1;10(5):1706-16.

doi: 10.1158/1078-0432.ccr-0951-3.

Y Gloria Meng, Michael Untch, He-Jing Wang, Ingo Bauerfeind, Melinda Epstein, Petra Stieber, Jean-Michel Vernes, Johnny Gutierrez, Kyu Hong, Malgorzata Beryt, Hermann Hepp, Dennis J Slamon, Mark D Pegram

Affiliations

• PMID: 15014023
• DOI: 10.1158/1078-0432.ccr-0951-3

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

Gottfried E Konecny et al. Clin Cancer Res. 2004.

Abstract

Purpose: Activation or overexpression of HER-2/neu is associated with up-regulation of vascular endothelial growth factor (VEGF) in human breast cancer cells in vitro. Preclinical experiments indicate that increased expression of VEGF may in part mediate the biologically aggressive phenotype of HER-2/neu-overexpressing human breast cancer. It was the purpose of this study to: (a). evaluate the association between HER-2/neu and VEGF expression in a large clinical cohort of primary breast cancer patients; (b). compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome.

Experimental design: HER-2/neu and VEGF were measured by ELISA in primary breast tumor tissue lysates from 611 unselected patients with a median clinical follow-up of 50 months. At least six VEGF isoforms consisting of 121, 145, 165, 183, 189, or 206 amino acids are generated as a result of alternative splicing. The VEGF(121-206) ELISA uses antibodies that bind to VEGF(121) and, therefore, detects all of the VEGF isoforms with 121 and more amino acids. The VEGF(165-206) ELISA uses antibodies that bind to VEGF(165) and, therefore, detects all of the VEGF isoforms with 165 and more amino acids. VEGF(121-206) and VEGF(165-206) were analyzed both as continuous and categorical variables, using detectable expression as a cutoff for positivity. Cell lines with defined HER-2/neu expression levels were used to establish a cutoff point for HER-2/neu overexpression in breast tumor samples.

Results: Our findings indicate a significant positive association between HER-2/neu and VEGF expression. VEGF(121-206) and VEGF(165-206) expression was detectable in 88 (77.2%) and 100 (87.7%), respectively, of the 114 patients with HER-2/neu-overexpressing tumors, in contrast to 271 (54.5%) and 353 (71.0%), respectively, of the 497 patients with nonoverexpressing tumors (chi(2) test: P < 0.001 for both VEGF(121-206) and VEGF(165-206)). VEGF(121-206) and VEGF(165-206) demonstrate a comparable prognostic significance for survival in unselected primary breast cancer patients (univariate analysis: VEGF(121-206), P = 0.0068; VEGF(165-206), P = 0.0046; multivariate analysis: VEGF(121-206), P = 0.1475; VEGF(165-206), P = 0.1483). When the analyses were performed separately for node-negative and node-positive patients, VEGF(121-206) and VEGF(165-206) were of prognostic significance for survival only in node-positive patients (univariate analysis: VEGF(121-206), P = 0.0003; VEGF(165-206), P = 0.0038; multivariate analysis: VEGF(121-206), P = 0.0103; VEGF(165-206), P = 0.0150). A biological concentration-effect relationship between VEGF expression and survival (VEGF(121-206), P = 0.0280; VEGF(165-206,) P = 0.0097) suggests that VEGF levels, as determined by ELISA, could be of importance as a predictive marker for therapeutic strategies that target VEGF. Combining HER-2/neu and VEGF(121-206)/VEGF(165-206) results in additional prognostic information for survival (VEGF(121-206), P = 0.0133; VEGF(165-206), P = 0.0092).

Conclusion: The positive association between HER-2/neu and VEGF expression implicates VEGF in the aggressive phenotype exhibited by HER-2/neu overexpression, and supports the use of combination therapies directed against both HER-2/neu and VEGF for treatment of breast cancers that overexpress HER-2/neu.

PubMed Disclaimer

Comment in

• Vascular endothelial growth factor in predicting outcome in breast cancer.
  Krippl P, Langsenlehner U, Samonigg H, Renner W, Köppel H. Krippl P, et al. Clin Cancer Res. 2004 Dec 15;10(24):8752-3. doi: 10.1158/1078-0432.CCR-04-1211. Clin Cancer Res. 2004. PMID: 15623662 No abstract available.

Similar articles

• Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
  Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. Konecny G, et al. Clin Cancer Res. 2001 Aug;7(8):2448-57. Clin Cancer Res. 2001. PMID: 11489825
• Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
  Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Konecny G, et al. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142. J Natl Cancer Inst. 2003. PMID: 12529347
• [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
  Zhang GH, Yang WT, Zhou XY, Zeng Y, Lu HF, Shi DR. Zhang GH, et al. Zhonghua Yi Xue Za Zhi. 2007 Jan 16;87(3):155-60. Zhonghua Yi Xue Za Zhi. 2007. PMID: 17425844 Chinese.
• The role of the HER-2/neu oncogene in gynecologic cancers.
  Cirisano FD, Karlan BY. Cirisano FD, et al. J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105. J Soc Gynecol Investig. 1996. PMID: 8796816 Review.
• The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
  Ross JS, Fletcher JA. Ross JS, et al. Semin Cancer Biol. 1999 Apr;9(2):125-38. doi: 10.1006/scbi.1998.0083. Semin Cancer Biol. 1999. PMID: 10202134 Review.

Cited by

• Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers.
  Huang X, Wu L, Liu Y, Xu Z, Liu C, Liu Z, Liang C. Huang X, et al. Br J Radiol. 2024 Sep 1;97(1161):1568-1576. doi: 10.1093/bjr/tqae124. Br J Radiol. 2024. PMID: 38991838
• Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy.
  Yehia L, Boulos F, Jabbour M, Mahfoud Z, Fakhruddin N, El-Sabban M. Yehia L, et al. PLoS One. 2015 Jun 5;10(6):e0129356. doi: 10.1371/journal.pone.0129356. eCollection 2015. PLoS One. 2015. PMID: 26046764 Free PMC article.
• Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View.
  Zarychta E, Ruszkowska-Ciastek B. Zarychta E, et al. Biomedicines. 2022 Jan 27;10(2):300. doi: 10.3390/biomedicines10020300. Biomedicines. 2022. PMID: 35203510 Free PMC article. Review.
• Targeted Therapy of Breast Cancer - New Insights and Perspectives.
  Bischoff J. Bischoff J. Breast Care (Basel). 2008;3(6):395-398. doi: 10.1159/000177226. Epub 2008 Dec 5. Breast Care (Basel). 2008. PMID: 21048909 Free PMC article. No abstract available.
• Targeted Therapy: Can It Substitute for Chemotherapy?
  Schütz F. Schütz F. Breast Care (Basel). 2008;3(4):257-261. doi: 10.1159/000149816. Epub 2008 Aug 20. Breast Care (Basel). 2008. PMID: 21076606 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal